Graham Neill

Global Medical Director
Sanofi, Reading, United Kingdom
Reading, England, United Kingdom

Presentation(s):

• OC 50.2 - Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study

  Tuesday, June 25, 2024
  09:45 – 10:00 ICT